Radiobiological Evaluation of Intensity Modulated Radiation Therapy Treatments of Patients with Head and Neck Cancer: A Dual-Institutional Study by Narayanasamy, G. et al.
University of Kentucky
UKnowledge
Radiation Medicine Faculty Publications Radiation Medicine
7-2015
Radiobiological Evaluation of Intensity Modulated
Radiation Therapy Treatments of Patients with
Head and Neck Cancer: A Dual-Institutional Study
G. Narayanasamy
University of Texas Health Science Center at San Antonio
A. P. Pyakuryal
University of Texas Health Science Center at San Antonio
S. Pandit
National Institutes of Health
J. Vincent
University of Texas Health Science Center at San Antonio
C. Lee
University of Texas Health Science Center at San Antonio
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/radmed_facpub
Part of the Radiology Commons
This Article is brought to you for free and open access by the Radiation Medicine at UKnowledge. It has been accepted for inclusion in Radiation
Medicine Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Narayanasamy, G.; Pyakuryal, A. P.; Pandit, S.; Vincent, J.; Lee, C.; Mavroidis, P.; Papanikolaou, N.; Kudrimoti, Mahesh; and Sio, T. T.,
"Radiobiological Evaluation of Intensity Modulated Radiation Therapy Treatments of Patients with Head and Neck Cancer: A Dual-
Institutional Study" (2015). Radiation Medicine Faculty Publications. 4.
https://uknowledge.uky.edu/radmed_facpub/4
Authors
G. Narayanasamy, A. P. Pyakuryal, S. Pandit, J. Vincent, C. Lee, P. Mavroidis, N. Papanikolaou, Mahesh
Kudrimoti, and T. T. Sio
Radiobiological Evaluation of Intensity Modulated Radiation Therapy Treatments of Patients with Head and
Neck Cancer: A Dual-Institutional Study
Notes/Citation Information
Published in Journal of Medical Physics, v. 40, no. 3, p. 165-169.
© 2015 Journal of Medical Physics.
This is an open access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-
commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Digital Object Identifier (DOI)
http://dx.doi.org/10.4103/0971-6203.165075
This article is available at UKnowledge: https://uknowledge.uky.edu/radmed_facpub/4
© 2015 Journal of Medical Physics | Published by Wolters Kluwer - Medknow
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neck cancer: A dual-institutional study
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ABSTRACT
In clinical practice, evaluation of clinical efficacy of treatment planning stems from the radiation oncologist’s experience 
in accurately targeting tumors, while keeping minimal toxicity to various organs at risk (OAR) involved. A more objective, 
quantitative method may be raised by using radiobiological models. The purpose of this work is to evaluate the potential 
correlation of OAR-related toxicities to its radiobiologically estimated parameters in simultaneously integrated boost (SIB) 
intensity modulated radiation therapy (IMRT) plans of patients with head and neck tumors at two institutions. Lyman model for 
normal tissue complication probability (NTCP) and the Poisson model for tumor control probability (TCP) models were used 
the head and neck region were used to establish the correlation between NTCP values of (a) bilateral parotids with clinically 
observed rates of xerostomia, (b) esophagus with dysphagia, and (c) larynx with dysphagia. The results of the study indicated 
a strong correlation between the severity of xerostomia and dysphagia with Lyman NTCP of bilateral parotids and esophagus, 
respectively, but not with the larynx. In patients without complications, NTCP values of these organs were negligible. Using 
appropriate radiobiological models, the presence of a moderate to strong correlation between the severities of complications 
with NTCP of selected OARs suggested that the clinical outcome could be estimated prior to treatment.
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Introduction
Treatment of head and neck cancers using intensity 
modulated radiation therapy (IMRT) is a promising 
technique due to its ability to conform high doses to 
irregularly shaped treatment volumes, and also the clever 
use of inverse planning techniques to steer radiation doses 
away from multiple critical normal organs. Two of the most 
common complications associated with IMRT of head and 
neck tumor treatments are xerostomia (inadequate and 
even lack of salivary production) and dysphagia (increased 
swallowing difficulty of the esophagus). While the former 
is reported to be due to irradiation of parotid tissues,[1] 
the latter is due to irradiation of pharyngeal constrictors, 
esophagus, and larynx;[2] both processes are biologically 
and physiologically complex.
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Lyman normal tissue complication probability (NTCP) 
model is one of the most popular radiobiological models 
typically used in modern dose-effect calculations.[3] This model 
is based on calculated dose volume histograms (DVH) of the 
organs at risk (OAR);[4-6] this work was detailed by Luxton et al. 
who outlined the key values of the main parameters, namely 
TD50,5, slope parameter (m), and the volume parameter (n).
[7] 
In this project, we introduced and evaluated the tumor control 
probability (TCP) and NTCP values of multiple targets and 
OARs, from their respective DVH statistics using the histogram 
analysis in radiation therapy (HART) software.[8] The treatment 
plans were clinically produced and strictly followed in regard to 
organ tolerances as established by the quantitative analyses of 
normal tissue effects in the clinic (QUANTEC) guidelines.[9]
Materials and Methods
Patient population
In this study, we focused on the toxicities observed in 
parotids, esophagus, and larynx. IMRT plans of the head 
and neck cancers were retrospectively reviewed in this study, 
which was approved by the Institutional Review Board at 
both institutions (Institutions 1, 2). Between 2009 and 
2011, 95 consecutive patients with oropharyngeal primaries 
were identified. Accessibility of the treatment plan and the 
follow-up data limited the available pool to 61 patients. 
Among these patients who received IMRT due to head and 
neck cancers, 33 (54%) cases whom developed clinically 
significant xerostomia (N = 23), dysphagia (N = 22), 
or both complications (N = 12) in the long-term were 
studied. All patients were treated using simultaneously 
integrated boost (SIB) technique; these 33 cases formed 
the cohort of this study. The mean age was 68 years (range: 
55–82 years). The follow-up time ranged from 1.5 to 
3.0 years from the end of treatment, with a mean of 
2.1 years. Free-breathing computed tomography (CTs) were 
acquired on a GE-LightSpeed 16-slice CT scanner (GE 
Healthcare, Waukesha, WI), and immobilization was 
generally acquired by the use of a thermoplastic mask. The 
patients were treated using a 6MV photon beam from 23EX 
linear accelerator (Varian Medical Systems, Palo Alto, CA, 
USA) with a multi-leaf collimator having 60 pairs of leaves. 
Nine (9) patients were treated using volumetric modulated 
arc therapy (VMAT) with two opposing arcs at a maximum 
dose rate of 600 MU/min. The remaining 24 cases were 
treated using 7–9 step and shoot IMRT beams in coplanar 
or noncoplanar configuration. The 33 patients were treated 
with the prescription dose (PD) ranging between 63.0 and 
70.2 Gy (average, 69.0 Gy) over 29–39 fractions (average, 
34 fractions). Up to 3 SIB-based target volumes (PTV1, 
PTV2, and PTV3) were delineated [Figure 1]. The mean 
value ± standard deviation of PTV1, PTV2, and PTV3 were 
317.0 ± 252.4 cc, 524.7 ± 359.7 cc, and 282.6 ± 121.8 cc, 
respectively. The Pinnacle TPS (ver. 7.6c, Philips Healthcare, 
The Netherlands) and XiO TPS (ver. 4.50, CMS, St Louis, 
USA) were used for treatment planning. The OARs included 
the parotid glands, nasopharynx, larynx, mandibles, optic 
structures, brainstem, spinal cord, brachial plexus, and whole 
brain. The treatment plan objectives were based on the 
QUANTEC guidelines. The contours, field arrangement, 
dose plan, and target conformity were approved by the 
respective institutional prescribing radiation oncologists.
Complications
The severity of complications was graded using the 
Common Terminology Criteria for Adverse Events guidelines 
(CTCAE ver. 4.0).[10] National Cancer Institute- based 
CTCAE has been widely accepted across the oncology 
community as the standard for adverse event grading. 
While grades 1, 2, and 3 stands for mild, moderate and 
severe symptoms, grades 4 and 5 are typically related to 
life-threatening consequences and death from the inciting 
adverse events, respectively. There was no grade 5 toxicity 
recorded in this study.
Radiobiological modeling
The TCP model predicts that cell killing is based on Poisson 
statistics. For a given heterogeneous dose distribution 
defined by discrete DVH (dDVH) values {Di, vi}, TCP is 
given by the following expression:[11]
1
2
D
TCD
nv ei i
TCP
2 50
50
l  2
=
i
  (1)
Where, TCD50 is the dose producing 50% TCP and 50 is 
the normalized slope at the 50% probability level. The PD 
considered in this study was the largest dosage prescribed to 
Figure 1: Transverse, sagittal, and coronal slices of computed tomography 
images of a patient with head and neck cancer treated by simultaneously 
integrated boost intensity modulated radiation therapy. In this particular 
example, three (3) PTV levels in yellow, green and orange receiving 5445, 
5940 and 6996 cGy were shown, respectively
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the PTVs. In TCP computation, the range of the reference 
values of Di used to estimate normalized volume (vi) was 
20%PD, 40% PD, 60% PD, 80% PD, 100% PD, 110% PD, 
and 120% PD.
The Lyman NTCP model for normal tissue irradiation 
was based on the sigmoidal dose-response relationship and 
the equivalent uniform dose (EUD) concept:
NTCP 50
50
EUD - TD
=
mD
 (2)
where 
x
t x
x dt erf
21 1
exp = 1+
2 22 2
The reference values of Di used to estimate vi in Lyman 
NTCP estimation were 25% PD, 50% PD, 75% PD, 
100% PD. The parameter m indicated the slope of the 
dose-response curve, and TD50 determined the position of a 
dose-response curve at the 50% probability of complication. 
EUD, or generalized equivalent uniform dose (gEUD), 
represented the uniform dose that would produce the same 
radiobiological effect as the given heterogeneous dose 
specified by the DVH.[12]
1
D
n
ngEUD vi ii
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Whereas, {Di, vi} were the dose-volume values in the 
dDVH and n determined the dose-volume dependence of a 
tissue which was deterministic based on tissue architecture 
differences.
The values that were used in this study for calculation 
of TCP and NTCP were obtained from Luxton et al.[7] 
For tumor control, TCD50 = 63.8 Gy, and / =10 Gy. For 
bilateral parotids, TD50,5 = 28.4 Gy, m = 0.18, and n = 1 
were applied. For esophagus, TD50,5 = 47 Gy, m = 0.36, and 
n = 0.69. Finally, for larynx, TD50,5 = 70 Gy, m = 0.17 and 
n = 0.08. The HART computational platform was used for 
calculating the TCP and NTCP values from DVH. The 
NTCP values of the three OARs reported above (calculated 
from HART program) were used to correlate toxicity levels 
which led to complications.[8]
As a baseline measurement, the NTCP values of the 
parotids, esophagus, and larynx were estimated for the 
remainder of the patient population without any reported 
long-term xerostomia or dysphagia complications.
Results
In the 33 IMRT head and neck cancer cases, the TCP and 
NTCP values were derived from the DVH statistics using 
HART program. CT slice of a representative patient with the 
highest PD of 69.96 Gy which was treated using VMAT is 
shown in Figure 1. The reference values of dose and fractional 
volumes used in computation of NTCP value of parotid 
glands of the representative patient were: (1749 cGy, 0.745), 
(3498 cGy, 0.517), (5247 cGy, 0.37), and (6996 cGy, 0.156). 
The patient had a NTCP value of 0.71 of parotid glands, 
and xerostomia severity of 2 by grade. Values were quoted as 
mean ± standard error at 95% confidence level (SE). For the 
patient population studied (N = 33), the mean ± SE TCP 
value was estimated to be 0.8 ± 0.03; while the NTCP values 
of the parotids, esophagus and larynx were 0.4 ± 0.1, 0.2 ± 0.1, 
and 0.1 ± 0.1, respectively. The PD ranged between 63.0 and 
70.2 Gy (mean dose prescribed was 69.0 Gy).
The severity of xerostomia was found to correlate 
well with the NTCP value of parotids, with a correlative 
strength of 0.63 (Pearson correlation coefficient value, R2), 
as shown in Figure 2a. Using a paired two-tailed Student’s 
t-test, statistical significant difference was observed 
with P < 0.01. The correlation between the severity of 
dysphagia and NTCP value of esophagus was also found 
to be statistically significant, with P < 0.01 and R2 = 0.74 
indicating strong correlation, as shown in Figure 2b. The 
solid line shows the best fit of the severity of complications 
with the NTCP values based on the available data; the line 
of best fit equations were measured at y = 1.38x + 0.89 for 
Figure 2: Correlation between the severity of (a) xerostomia and (b) 
dysphagia with the Lyman normal tissue complication probability indices 
of bilateral parotid glands for TD50,5 = 28.4 Gy (R2 = 0.63, P < 0.01) and 
esophagus for TD50,5 = 47Gy (R2 = 0.74, P < 0.01), respectively
a
b
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xerostomia, and y = 5.75x + 0.89 for dysphagia, where y 
represents the severity of complication by grade, and x being 
the calculated NTCP values. However, the Lyman model 
provided a very poor correlation between dysphagia severity 
and NTCP of the larynx (R2 = 0.01, which indicated a poor 
level of correlation). In addition, no correlation was found 
between the complication severity and the PD or DVH 
values for any of the three organs.
In a sub-group study of 15 patients treated at higher PDs 
of 70 ± 0.3 Gy, grade 2 + xerostomia, and 3 + dysphagia 
toxicities were observed in 9 and 7 patients, respectively. In 
this sub-group, the corresponding mean ± SE NTCP values 
were 0.7 ± 0.1 (N = 15) for parotids and 0.4 ± 0.04 (N = 15) 
for esophagus, respectively.
From the baseline study on patients without any report 
of xerostomia or dysphagia complications, the mean ± SE 
values of NTCP of parotids, esophagus and larynx were 
found to be 0.06 ± 0.03, 0.05 ± 0.02, and 0.04 ± 0.04, 
respectively. The mean ± SE TCP value was estimated to 
be 0.75 ± 0.05.
Discussion
The IMRT dosimetric planning objectives of head and 
neck tumors were similar across patients and followed 
the guidelines outlined in QUANTEC.[9] However, the 
radiation-related complications which occurred in patients 
may depend on various dosimetric and radiobiological 
factors including the spatial distance of OAR’s from the 
tumor, beam weighting, and OAR classification based on 
functional subunits; it is certainly multifactorial across a 
number of different domains in the realms of clinical and 
biological radiation oncology.
Our study looked at a few complications that were prevalent 
among the head and neck tumor patients who received IMRT. 
A pattern of correlation was identified between the severity 
of complications and the NTCP of three organs of interest. 
Among the three possible correlations, only 2 (xerostomia 
and dysphagia for parotid and esophageal toxicities, 
respectively) were considered significant on the two-tailed 
Student’s t-test and the Pearson correlation coefficients; 
however, the number of cases in this study were limited. 
Among the patients with neither of the two complications, 
NTCP of the three OARs were found to be negligible. The 
correlation between the corresponding toxicities and NTCPs 
of the examined OARs depends on the availability of the 
proper dosimetric information and the accuracy of clinical 
follow-up data on the reported toxicity levels.
A multicenter study showed that among many factors, 
the mean parotid dose was the most important predictor of 
moderate to severe xerostomia at 6 months.[13] However, no 
long term toxicity data were mentioned in their work. Roesnik 
et al. modeled the reduction of individual parotid flow rates 
using the LKB model.[14] Many studies demonstrated that 
the salivary flow could be reduced exponentially with a mean 
parotid gland threshold dose above 26 Gy.[15,16] Quantitative 
models describing the reduction of the parotid function 
with the dose distribution over the major and minor salivary 
glands were previously reported.[17-19]
Increased dose to a large volume of swallowing structures 
is reported to result in higher levels of dysphagia in a number 
of studies.[20-22] In a study on 82 head and neck tumor patients 
treated with SIB-IMRT, long term dysphagia was related to 
radiation dose delivered to the swallowing structures.[23] 
Taking into account the complex sequence of swallowing 
event, it is highly unlikely a single structure is important. 
Even though xerostomia can be reduced with parotid-sparing 
IMRT, the comparable advances in successful reduction of 
dysphagia toxicities have been largely limited.
Conclusion
This study suggested that a moderate to strong correlation 
may exist between the severities of xerostomia and also 
dysphagia, with the calculated NTCP values of bilateral 
parotids and esophagus as OARs, respectively. The existence 
of a reasonable degree of correlation between the observed 
complication rates and NTCP values demonstrates that 
clinically apparent complications or side effects may 
be further improved by using selective radiobiological 
parameters in radiotherapy planning that are directly 
derived from appropriate models.
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